Inhaled RNS60 Vapour Study
Research type
Research Study
Full title
Systemic Bioactivity of Inhaled Nebulized RNS60
IRAS ID
178333
Contact name
Aldona Greenwood
Contact email
Sponsor organisation
Revalesio Corporation
Eudract number
2015-001592-46
Duration of Study in the UK
0 years, 3 months, 31 days
Research summary
Inhaled nebulized RNS60 is being developed as a novel treatment for asthma. Whether inhaled RNS60 has therapeutic effects outside of the lung is not known. This study will determine whether inhaled RNS60 reduces exercise induced muscle damage and markers of inflammation compared with inhaled placebo. The ability to measure a systemic response to inhaled RNS60 will support its testing for the treatment of other diseases.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
15/LO/0818
Date of REC Opinion
24 Jun 2015
REC opinion
Further Information Favourable Opinion